Bavarian Nordic A/S
Bavarian Nordic A/S
11/07/2025 | Press release | Archived content
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
Bavarian Nordic Announces Major Shareholder Notification from Morgan Stanley
COPENHAGEN, Denmark, November 7, 2025 - Pursuant to section 30 of the Danish Capital Markets Act, Bavarian Nordic A/S hereby announces that the Company has received notification from Morgan Stanley that they hold 5,13% of the shares and voting rights in Bavarian Nordic A/S as of October 31, 2025.
About Bavarian Nordic
Bavarian Nordic is a global vaccine company with a mission to improve health and save lives through innovative vaccines. We are a preferred supplier of mpox and smallpox vaccines to governments to enhance public health preparedness and have a leading portfolio of travel vaccines. For more information, visit https://www.bavarian-nordic.com.
Contact investors:
Europe: Disa Tuominen, IR Manager, [email protected]
US: Graham Morrell, Gilmartin Group, [email protected], Tel: +1 781 686 9600
Contact media:
Nicole Seroff, Vice President Corporate Communications, [email protected], Tel: +45 53 88 06 03
Company Announcement no. 41 / 2025
Published on November 07, 2025, 17:30 CET
Bavarian Nordic A/S published this content on November 07, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on November 09, 2025 at 18:53 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]